Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT02511106

PHASE3

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy

Official title: A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA).

Key Details

Gender

All

Age Range

18 Years - 130 Years

Study Type

INTERVENTIONAL

Enrollment

682

Start Date

2015-10-21

Completion Date

2029-01-31

Last Updated

2026-03-30

Healthy Volunteers

Conditions

Stage IB-IIIA Non-small Cell Lung Carcinoma

Interventions

DRUG

AZD9291 80 mg/40 mg

The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.

DRUG

Placebo AZD9291 80 mg/40 mg

The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.

DRUG

Open-label AZD9291 80 mg/40 mg

Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.

Inclusion Criteria: 1. Male or female, aged at least 18 years. 2. Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology 3. MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care. 4. Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria. 5. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M. 6. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. 7. Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization. 8. World Health Organization Performance Status of 0 to 1. 9. Female patients should be using adequate contraceptive measures, should not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-child-bearing potential. Exclusion Criteria: 1. Treatment with any of the following: * Pre-operative or post-operative or planned radiation therapy for the current lung cancer * Pre-operative (neo-adjuvant) platinum based or other chemotherapy * Any prior anticancer therapy * Prior treatment with neoadjuvant or adjuvant EGFR-TKI at any time * Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug * Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4 * Treatment with an investigational drug within five half-lives of the compound or any of its related material. 2. Patients who have had only segmentectomies or wedge resections 3. History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for \> 5 years following the end of treatment. 4. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy. 5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). 6. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291. 7. Any of the following cardiac criteria: * Mean resting corrected QT interval (QTc) \>470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value. * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG. * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval. 8. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD. 9. Inadequate bone marrow reserve or organ function.

Locations (238)

Research Site

Los Angeles, California, United States

Research Site

Santa Monica, California, United States

Research Site

Santa Rosa, California, United States

Research Site

Torrance, California, United States

Research Site

Grand Junction, Colorado, United States

Research Site

New Haven, Connecticut, United States

Research Site

Norwalk, Connecticut, United States

Research Site

Fort Myers, Florida, United States

Research Site

Pembroke Pines, Florida, United States

Research Site

St. Petersburg, Florida, United States

Research Site

Athens, Georgia, United States

Research Site

Honolulu, Hawaii, United States

Research Site

Chicago, Illinois, United States

Research Site

Elk Grove Village, Illinois, United States

Research Site

Bethesda, Maryland, United States

Research Site

Brick, New Jersey, United States

Research Site

Florham Park, New Jersey, United States

Research Site

Mineola, New York, United States

Research Site

Pawtucket, Rhode Island, United States

Research Site

Chattanooga, Tennessee, United States

Research Site

Nashville, Tennessee, United States

Research Site

San Antonio, Texas, United States

Research Site

Fort Belvoir, Virginia, United States

Research Site

Bedford Park, Australia

Research Site

Camperdown, Australia

Research Site

Darlinghurst, Australia

Research Site

Heidelberg, Australia

Research Site

Kogarah, Australia

Research Site

Kurralta Park, Australia

Research Site

Woolloongabba, Australia

Research Site

Brussels, Belgium

Research Site

Brussels, Belgium

Research Site

Ghent, Belgium

Research Site

Kortrijk, Belgium

Research Site

Barretos, Brazil

Research Site

Cachoeira de Itapemirim, Brazil

Research Site

Curitiba, Brazil

Research Site

Florianópolis, Brazil

Research Site

Fortaleza, Brazil

Research Site

Lajeado, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Rio de Janeiro, Brazil

Research Site

Salvador, Brazil

Research Site

São José do Rio Preto, Brazil

Research Site

São Paulo, Brazil

Research Site

Toronto, Ontario, Canada

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Changchun, China

Research Site

Dalian, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Kunming, China

Research Site

Nanjing, China

Research Site

Nanning, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Suzhou, China

Research Site

Tianjin, China

Research Site

Tianjin, China

Research Site

Tianjin, China

Research Site

Ürümqi, China

Research Site

Xi'an, China

Research Site

Xiamen, China

Research Site

Yangzhou, China

Research Site

Zhengzhou, China

Research Site

Bron, France

Research Site

Lille, France

Research Site

Limoges, France

Research Site

Lyon, France

Research Site

Paris, France

Research Site

Aachen, Germany

Research Site

Berlin, Germany

Research Site

Berlin, Germany

Research Site

Berlin, Germany

Research Site

Cologne, Germany

Research Site

Coswig, Germany

Research Site

Gauting, Germany

Research Site

Gerlingen, Germany

Research Site

Großhansdorf, Germany

Research Site

Halle, Germany

Research Site

Hamburg, Germany

Research Site

Homburg, Germany

Research Site

Immenhausen, Germany

Research Site

Kassel, Germany

Research Site

Lübeck, Germany

Research Site

Würzburg, Germany

Research Site

Hong Kong, Hong Kong

Research Site

Hong Kong, Hong Kong

Research Site

King's Park, Hong Kong

Research Site

Budapest, Hungary

Research Site

Budapest, Hungary

Research Site

Deszk, Hungary

Research Site

Székesfehérvár, Hungary

Research Site

Törökbálint, Hungary

Research Site

Beersheba, Israel

Research Site

Haifa, Israel

Research Site

Jerusalem, Israel

Research Site

Kfar Saba, Israel

Research Site

Petah Tikva, Israel

Research Site

Ramat Gan, Israel

Research Site

Tel Aviv, Israel

Research Site

Bari, Italy

Research Site

Bergamo, Italy

Research Site

Bologna, Italy

Research Site

Cremona, Italy

Research Site

Florence, Italy

Research Site

Lucca, Italy

Research Site

Meldola, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Novara, Italy

Research Site

Orbassano, Italy

Research Site

Padova, Italy

Research Site

Parma, Italy

Research Site

Roma, Italy

Research Site

Bunkyō City, Japan

Research Site

Fukuoka, Japan

Research Site

Hirakata-shi, Japan

Research Site

Hiroshima, Japan

Research Site

Hiroshima, Japan

Research Site

Kanazawa, Japan

Research Site

Kashiwa, Japan

Research Site

Kitakyushu-shi, Japan

Research Site

Kobe, Japan

Research Site

Kurume-shi, Japan

Research Site

Matsuyama, Japan

Research Site

Nagoya, Japan

Research Site

Niigata, Japan

Research Site

Osakasayama-shi, Japan

Research Site

Sagamihara-shi, Japan

Research Site

Sakaishi, Japan

Research Site

Sasebo-shi, Japan

Research Site

Sendai, Japan

Research Site

Shinjuku-ku, Japan

Research Site

Sunto-gun, Japan

Research Site

Ube-shi, Japan

Research Site

Yokohama, Japan

Research Site

Yokohama, Japan

Research Site

Yonago-shi, Japan

Research Site

Amsterdam, Netherlands

Research Site

Arnhem, Netherlands

Research Site

Hoofddorp, Netherlands

Research Site

Zwolle, Netherlands

Research Site

Krakow, Poland

Research Site

Lodz, Poland

Research Site

Otwock, Poland

Research Site

Poznan, Poland

Research Site

Racibórz, Poland

Research Site

Warsaw, Poland

Research Site

Wieliszew, Poland

Research Site

Bucharest, Romania

Research Site

Bucharest, Romania

Research Site

Cluj-Napoca, Romania

Research Site

Craiova, Romania

Research Site

Focşani, Romania

Research Site

Iași, Romania

Research Site

Timișoara, Romania

Research Site

Arkhangelsk, Russia

Research Site

Kazan', Russia

Research Site

Moscow, Russia

Research Site

Moscow, Russia

Research Site

Obninsk, Russia

Research Site

Omsk, Russia

Research Site

Pyatigorsk, Russia

Research Site

Rostov-on-Don, Russia

Research Site

Ryazan, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Cheongju-si, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Suwon, South Korea

Research Site

Suwon, South Korea

Research Site

A Coruña, Spain

Research Site

Barcelona, Spain

Research Site

Donostia / San Sebastian, Spain

Research Site

Elche, Spain

Research Site

Las Palmas de Gran Canaria, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Majadahonda, Spain

Research Site

Málaga, Spain

Research Site

Valencia, Spain

Research Site

Valencia, Spain

Research Site

Zaragoza, Spain

Research Site

Linköping, Sweden

Research Site

Changhua, Taiwan

Research Site

Putzu City, Taiwan

Research Site

Taichung, Taiwan

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan District, Taiwan

Research Site

Bangkok, Thailand

Research Site

Bangkok, Thailand

Research Site

Chiang Rai, Thailand

Research Site

Khon Kaen, Thailand

Research Site

Mueang, Thailand

Research Site

Phitsanulok, Thailand

Research Site

Songkhla, Thailand

Research Site

Ankara, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Bursa, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Izmir, Turkey (Türkiye)

Research Site

Dnipro, Ukraine

Research Site

Lviv, Ukraine

Research Site

Sumy, Ukraine

Research Site

Uzhhorod, Ukraine

Research Site

Vinnytsia, Ukraine

Research Site

Zaporizhzhia, Ukraine

Research Site

Hanoi, Vietnam

Research Site

Hanoi, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Clinical Research Directory

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (238)